

UW Division of Rheumatology Affiliate Faculty Sessions at ACR

Friday November 6, 2020

Time, Location:	Session Type:	Title:	Authors/Speakers/Facilitators:
9:00-11:00am Abstract ID: 0346	Poster Presentation	Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients with Active Psoriatic Arthritis	Philip Mease
9:00-11:00am Abstract ID: 0347	Poster Presentation	In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20)	Philip Mease
9:00-11:00am Abstract ID: 0349	Poster Presentation	Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year	Philip Mease
9:00-11:00am Abstract ID: 0355	Poster Presentation	Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial	Philip Mease
9:00-11:00am Abstract ID: 0359	Poster Presentation	Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic	Philip Mease

		Arthritis/Spondyloarthritis Registry	
9:00-11:00am Abstract ID: 0366	Poster Presentation	Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab	Philip Mease
9:00-11:00am Abstract ID: 0367	Poster Presentation	Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2)	Philip Mease
9:00-11:00am Abstract ID: 0368	Poster Presentation	Comparable Impact and Burden of Disease of Psoriatic Arthritis Patients with Limited Joint Involvement vs. Those with More Extensive Joint Involvement: Interim Results from a Prospective, Multicenter, Real-World Study in Patients Treated with Apremilast	Philip Mease
9:00-11:00am Abstract ID: 0381	Poster Presentation	Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis	Philip Mease
9:00-11:00am Abstract ID: 0506	Poster Presentation	Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through Week 52 of a Phase 3, Randomized, Double-blind, Placebo-controlled Study	Philip Mease

		Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis	
--	--	--	--

Saturday November 7, 2020

Time, Location:	Session Type:	Title:	Authors/Speakers/Facilitators:
9:00-11:00am Abstract ID: 0895	Poster Presentation	Effects of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19-Subunit of Interleukin-23, on Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Pooled Results Through Week 24 from Two Phase 3 Studies	Philip Mease
9:00-11:00am Abstract ID: 0905	Poster Presentation	Probability of Achieving Low Disease Activity or Remission with Apremilast Treatment Among DMARD-Naive Subjects with Active Psoriatic Arthritis	Philip Mease
9:00-11:00am Abstract ID: 0907	Poster Presentation	Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA)	Philip Mease
9:00-11:00am	Poster Presentation	Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline Demographic and Disease Characteristics: Pooled Results of Two Phase 3,	Philip Mease

		Randomized, Placebo- Controlled Studies	
--	--	--	--

Sunday November 8, 2020

Time, Location:	Session Type:	Title:	Authors/Speakers/Facilitators:
9:00-11:00am Abstract ID: 1349	Poster Presentation	Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis	Philip Mease
9:00-11:00am Abstract ID: 1363	Poster Presentation	Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial	Philip Mease
9:00-11:00am	Poster Presentation	Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial	Philip Mease